# Safety and Tolerability Study for Age-Related Macular Degeneration

> **NCT01485588** · PHASE1,PHASE2 · COMPLETED · sponsor: **Iconic Therapeutics, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** hI-con1™ 60µl
- **DRUG:** hI-con1™ 150µl
- **DRUG:** hI-con1™ 300µl

## Key facts

- **NCT ID:** NCT01485588
- **Lead sponsor:** Iconic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485588, "Safety and Tolerability Study for Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01485588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*